Oral antibiotic therapy in infective endocarditis.
The mortality of IE remains fairly high despite the aggressive use of intravenous antibiotics. Oral treatment of IE is an intriguing concept with many potential advantages over conventional intravenous therapy. Unfortunately, there are insufficient data to justify predominantly oral regimens for the treatment of IE. Trials have shown that oral therapy may have a role in follow-up to short courses of parenteral antibiotics, but these trials are limited by the small number of patients studied. It is important to note that most data for oral treatment of IE have been obtained from studies in patients with histories of IVDA and right-sided S. aureus endocarditis. As mentioned previously, the course of IE in this patient population tends to be less severe, which makes extrapolation of these data to the general population difficult. A need exist for the development of oral antimicrobials with the properties previously mentioned, making them appropriate for use in IE. Currently available oral agents require further study before general recommendations regarding their use in patients with IE can be made. Although successful oral treatment of prosthetic valve endocarditis has been reported, such patients in general should not be considered as appropriate candidates for oral therapy. For now, oral antimicrobial therapy may be appropriate only as follow-up to short-course intravenous therapy, or use in combination with intravenous therapy for IE in select populations whose disease course is less severe or in whom prolonged intravenous therapy is impractical (i.e., intravenous drug users).